Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06265688 2026-03-25

First In Human Study of CX-2051 in Advanced Solid Tumors

Phase 1 Recruiting

160 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT05101070 2026-03-18

aCCeleR8-001

Phase 1/2 Recruiting

282 enrolled

Other solid neoplasm

Solid Tumors

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Clinical Trials

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

COMBINE-EGFR-1

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

RAINFOL-01

First In Human Study of CX-2051 in Advanced Solid Tumors

aCCeleR8-001

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

VIT-B

MiST

MAPS

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

VITAC

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Bevacizumab in Treating Patients With Advanced Solid Tumors

Metronomic

CNTO95/Avastin

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

BEP

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Bevacizumab in Treating Young Patients With Refractory Solid Tumors